Announcements Trials

Browse Landscape

Phase

Phase 2 43 Phase 1 11 Phase 3 6 Phase NA 4 Phase 4 2 Phase 2/3 2 Phase 1/2 1

Status

Unknown 22 Recruiting 4 Terminated 1 Not yet recruiting 1 Completed 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Interventions

Cyclophosphamide 142 Gemcitabine 129 Paclitaxel 125 Radiotherapy 119 Cisplatin 111 Carboplatin 111 pembrolizumab 109 Nivolumab 106 Docetaxel 90 Rituximab 86 Lenalidomide 77 Dexamethasone 76 Cytarabine 69 Bevacizumab 64 Fluorouracil 63 Etoposide 63 Oxaliplatin 62 Filgrastim 59 Peripheral Blood Stem Cell Transplantation 58 Everolimus 58 Capecitabine 58 fludarabine phosphate 57 Doxorubicin 56 Temozolomide 55 Prednisone 54 Irinotecan 53 Cetuximab 50 fludarabine 48 Ipilimumab 48 Erlotinib Hydrochloride 48

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Completed × apatinib × Clear all

NCT01497704 2017-10-02

Dose-Escalation and Safety Trial of YN968D1

Elevar Therapeutics

Phase 1/2 Completed

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡